Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-05-17
2010-06-08
Whiteman, Brian (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
07732421
ABSTRACT:
RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.
REFERENCES:
patent: 6506559 (2003-01-01), Fire et al.
patent: 6573099 (2003-06-01), Graham
patent: 2005/0227935 (2005-10-01), McSwiggen et al.
patent: 2005/0246794 (2005-11-01), Khvorova
patent: 2005/0255487 (2005-11-01), Khvorova et al.
patent: 2009/0247604 (2009-10-01), Tang et al.
patent: WO 00/27421 (2000-05-01), None
patent: 01/30360 (2001-03-01), None
patent: 01/30395 (2001-03-01), None
patent: WO 02/48168 (2002-06-01), None
patent: WO 2004/080406 (2004-09-01), None
patent: 2004/113387 (2004-12-01), None
Singh, et al., “Cytokine stimulated vascular cell adhesion molecule-1 (VCAM-1) ectodomain release is regulated by TIMP-3”, Jul. 1, 2005; vol. 67; No. 1; pp. 39-49; Cardiovascular Research.
Franchimont, et al. “Interleukin-6 receptor shedding is enhanced by interleukin-1beta and tumor necrosis factor alpha and is partially mediated by tumor necrosis factor alpha-converting enzyme in osteoblast-like cells”; Jan. 2005; vol. 52; No. 1; pp. 84-93; Arthritis and Rheumatism.
Shao, et al.; “Cigarette smoke induces MUC5A Mucin overproduction via tumor necrosis factor-alpha-converting enzyme in human airway epithelial (NCI-H292) cells”; Aug. 2004; vol. 287; No. 2; pp. L420-L427; American Journal of Physiology, Lung Cellular and Molecular Physiology.
Sutheesopon, et al.; Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide; May 2005; vol. 203; No. 2; pp. 387-397; Journal of Cellular Physiology.
Hu, et al.; “Autocrine tumor necrosis factor alpha links endoplasmic reticulum stress to the membrane death receptor pathway through IRE1alpha-mediated NF-kappaB activation, and down-regulation of TRAF2 expression”; Apr. 2006; vol. 26; No. 8; pp. 3071-3084; Molecular and Cellular Biology.
Chen, et al.; “Urothelial lesion formation is mediated by TNRF1 during neurogenic cystitis”; Oct. 2006; vol. 291; No. 4; pp. F741-F749; American Journal of Physiology, Renal Physiologyhen, et al.; “Urothelial lesion formation is mediated by TNRF1 during neurogenic cystitis”; Oct. 2006; vol. 291; No. 4; pp. F741-F749; American Journal of Physiology, Renal Physiology.
Bandyopadhyay, et al; “Interleukin-1alpha stimulates non-amyloidogenic pathway by alpha-secretase (ADAM-10 and ADAM-17) cleavage of APP in human astrocytic cells involving p38 MAP kinase”; Jul. 2006; vol. 84; No. 1; pp. 106-118.
Zhan, et al.; “TACE release of TNF-alpha mediates mechanotransduction-induced activation of p38 MAPK and myogenesis”; Feb. 2007; vol. 120; No. Pt 4; pp. 692-701; Journal of Cell Science.
Kenny, et al.; Targeting TACE-dependent EGFR ligand shedding in breast cancer; Feb. 2007; vol. 117; No. 2; pp. 337-345; The Journal of Clinical Investigation.
Castanotto, et al., “Functional siRNA expression from transfected PCR products”; 2002; vol. 8; pp. 1454-1460; RNA.
Kim, et al.; “Synthetic dsRNA dicer substrates enhance RNAi potency and efficacy” Feb. 2005; vol. 23; No. 2; pp. 222-226; Nature Biotechnology.
Marsh, et al.; “Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in sjogren syndrome” Apr. 1999; vol. 106; No. 4; pp. 811-816; Ophthalmology.
Offord, et al.; “Immortalized human corneal epithelial cells for ocular toxicity and inflammation studies” May 1999; vol. 40; No. 6; pp. 1091-1101; Investigative Ophthalmology & Vision Science.
Chatterton Jon E.
Gamache Daniel A.
Miller Steven T.
Senchyna Diane Michelle
Yanni John M.
Alcon Research, Ltd.
Derry Jason J.
Whiteman Brian
LandOfFree
RNAI-mediated inhibition of tumor necrosis factor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with RNAI-mediated inhibition of tumor necrosis factor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and RNAI-mediated inhibition of tumor necrosis factor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4174054